Kanda Tatsuo, Sasaki-Tanaka Reina, Tsuchiya Atsunori, Terai Shuji
Division of Gastroenterology and Hepatology, Uonuma Institute of Community Medicine, Niigata University Medical and Dental Hospital, Minamiuonuma 949-7302, Niigata, Japan.
Division of Gastroenterology and Hepatology, Graduate School of Medical and Dental Sciences, Niigata University, Niigata 951-8520, Japan.
World J Hepatol. 2025 Jan 27;17(1):99209. doi: 10.4254/wjh.v17.i1.99209.
Hepatitis B virus (HBV) infection causes acute and chronic hepatitis, compensated and decompensated cirrhosis, and hepatocellular carcinoma worldwide. The actual status of HBV infection and its treatment in certain regions of Asian and African countries, including Ethiopia, has not been well-documented thus far. Antiviral therapy for HBV infection can prevent the progression of HBV-related liver diseases and decrease the HBV-related symptoms, such as abdominal symptoms, fatigue, systemic symptoms and others. In Eastern Ethiopia, HBV-infected patients with cirrhosis were found to be positive for the HBV e antigen and to have a higher viral load than those without cirrhosis. Notably, 54.4% of patients practiced khat chewing and 18.1% consumed excessive amounts of alcohol. Tenofovir disoproxil fumarate effectively suppressed HBV DNA in those infected with HBV. It is important to elucidate the actual status of HBV infection in Eastern Ethiopia to eliminate HBV infection worldwide by 2030. HBV vaccination and the educational programs for Health Science students that provide practical strategies could help to reduce HBV infection in Eastern Ethiopia.
乙型肝炎病毒（HBV）感染在全球范围内可引发急性和慢性肝炎、代偿期和失代偿期肝硬化以及肝细胞癌。包括埃塞俄比亚在内的亚洲和非洲部分地区的HBV感染实际状况及其治疗情况，迄今尚未得到充分记录。HBV感染的抗病毒治疗可预防HBV相关肝病的进展，并减轻HBV相关症状，如腹部症状、乏力、全身症状等。在埃塞俄比亚东部，发现肝硬化的HBV感染患者HBV e抗原呈阳性，且病毒载量高于无肝硬化的患者。值得注意的是，54.4%的患者有咀嚼恰特草的习惯，18.1%的患者饮酒过量。替诺福韦酯有效地抑制了HBV感染者的HBV DNA。为在2030年在全球消除HBV感染，阐明埃塞俄比亚东部的HBV感染实际状况很重要。HBV疫苗接种以及为健康科学专业学生提供实用策略的教育项目，有助于减少埃塞俄比亚东部的HBV感染。
